Merck & Co., Inc. (NYSE:MRK) is one of the Best Dividend Leaders to Buy Now. Merck & Co., Inc. (NYSE:MRK) has struggled over the past year, with its stock falling nearly 40%, partly due to concerns ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Corrections & Amplifications for the edition of June 24, 2025 ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...

Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma.

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their ...